Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

EchoAnalysis8 Apr. 19 at 7:21 PM

$ABCL calm before the move 👀 Price is approaching the 200 DMA from below It’s simple — flip this level to support and it’s a buy Wave 5 target: +206% 🚀

0 · Reply

Kaykay610 Apr. 19 at 2:29 PM

$ABCL https://x.com/i/status/2045381731927085537 Looks like things are moving behind the scenes. When this thing moves it will run

1 · Reply

UncleTomFlorida Apr. 19 at 1:44 PM

$ABCL https://x.com/jinseongeo83473/status/2045774988553371783?s=20

0 · Reply

snowPOW Apr. 19 at 5:50 AM

$ABCL everything that I want to see, is essentially happening here. Great, slow growth, then poof* Millionaire maker here; CEO is focused, driven and smarter than me. Thanks for the "cheaps"

0 · Reply

chamono1942 Apr. 19 at 12:54 AM

$ABCL Let's go up to ten dollars!

0 · Reply

snowPOW Apr. 18 at 11:13 PM

$ABCL great week

0 · Reply

MorganHoratio Apr. 18 at 7:54 PM

20 Small Cap Stocks Across 20 Sectors — A 5-Year Framework（11-15） $SERV — Delivery Robotics $ZETA — AI powered marketing $EVER — Insurtech $PATH — Enterprise automation $ABCL — AI drug discovery All eyes are on $ZETA's upcoming earnings (April 30)—a critical litmus test for AI monetization. For $SERV, watch out for recent insider selling; while the narrative is strong, short-term profit-taking is a risk. Which of these "Pragmatic AI" sectors—Delivery, Marketing, or Automation—do you think will lead the pack in H2 2026? Drop your case in the comments!

1 · Reply

Odoji Apr. 18 at 5:11 PM

$ABCL idk but this board still gives me pltr vibes when it was in teens ironically bout the time I started my position here 😂

1 · Reply

Rastafari Apr. 18 at 4:54 PM

$ABCL Four new jobs added on their web site this month. 2 for QC and 2 for In Vivo specialists respectively. Things are picking up!

0 · Reply

Odoji Apr. 18 at 4:52 PM

$ABCL

0 · Reply

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Feb 24, 2026, 4:05 PM EST - 7 weeks ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 2 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 3 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 12, 2026, 9:00 AM EST - 3 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 4 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 4 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Nov 10, 2025, 9:00 AM EST - 5 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 4:05 PM EST - 5 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 7 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 8 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 4:05 PM EDT - 9 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 11 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Feb 23, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Resignation of Board Member

Feb 22, 2024, 8:15 PM EST - 2 years ago

AbCellera to Present at Upcoming Investor Conferences in March

EchoAnalysis8 Apr. 19 at 7:21 PM

$ABCL calm before the move 👀 Price is approaching the 200 DMA from below It’s simple — flip this level to support and it’s a buy Wave 5 target: +206% 🚀

0 · Reply

Kaykay610 Apr. 19 at 2:29 PM

$ABCL https://x.com/i/status/2045381731927085537 Looks like things are moving behind the scenes. When this thing moves it will run

1 · Reply

UncleTomFlorida Apr. 19 at 1:44 PM

$ABCL https://x.com/jinseongeo83473/status/2045774988553371783?s=20

0 · Reply

snowPOW Apr. 19 at 5:50 AM

$ABCL everything that I want to see, is essentially happening here. Great, slow growth, then poof* Millionaire maker here; CEO is focused, driven and smarter than me. Thanks for the "cheaps"

0 · Reply

chamono1942 Apr. 19 at 12:54 AM

$ABCL Let's go up to ten dollars!

0 · Reply

snowPOW Apr. 18 at 11:13 PM

$ABCL great week

0 · Reply

MorganHoratio Apr. 18 at 7:54 PM

1 · Reply

Odoji Apr. 18 at 5:11 PM

$ABCL idk but this board still gives me pltr vibes when it was in teens ironically bout the time I started my position here 😂

1 · Reply

Rastafari Apr. 18 at 4:54 PM

$ABCL Four new jobs added on their web site this month. 2 for QC and 2 for In Vivo specialists respectively. Things are picking up!

0 · Reply

Odoji Apr. 18 at 4:52 PM

$ABCL

0 · Reply

DeMampCamp Apr. 17 at 8:17 PM

$ABCL Nice close going into the weekend! Up from here my friends! Cheers and have a wonderful weekend!

1 · Reply

Rastafari Apr. 17 at 7:00 PM

$ABCL let’s take a quick poll: who thinks we end at $4 today?

1 · Reply

JennyRowes Apr. 17 at 5:38 PM

$ABCL short ratio = 19… just need a spark of good news and this will explode

1 · Reply

DeMampCamp Apr. 17 at 4:09 PM

$ABCL Let's grab $4 by the ****y!

1 · Reply

UncleTomFlorida Apr. 17 at 3:57 PM

$ABCL https://x.com/nick88886666/status/2045108003003846728?s=20

0 · Reply

DeMampCamp Apr. 17 at 3:22 PM

$ABCL Insane amount of shares have been stacked on the ASK at $3.90 /$3.91 the last 2 days, not too sure what to think of it

0 · Reply

TheDrunkTrader69 Apr. 17 at 2:28 PM

$ABCL This is your buy and hold stock, long term for me buying regardless $$$

0 · Reply

DragonAlgo Apr. 17 at 2:11 PM

🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.03 Stop: $0.02 TP1: $0.04 TP2: $0.05 TP3: $0.07 Active momentum environment. 🔗 https://dragonalgo.com

0 · Reply

SultanK Apr. 17 at 2:07 PM

$ABCL 2026-04-10 12:30:00 GMT DJ AbCellera Biologics Price Target Announced at $11.00/Share by Jones Trading

0 · Reply

MTRADe_01 Apr. 17 at 2:07 PM

$ABCL $AMPX Watching for: • pullback → base • continuation with volume Not early enough for full size yet, but on watch for rotation. $IONQ $AI $PLTR

0 · Reply

tradersunion353 Apr. 17 at 1:49 PM

$ABCL already pos is trying to go red market is trading at record highs waiting for those adding and loading folks here 😂😂😂

0 · Reply

DeMampCamp Apr. 17 at 1:44 PM

$ABCL Damn, shorts and short term traders sure did unload on that rip above , filled the gap and back up from here!

1 · Reply

Market Cap	1.22B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	4,808,500
Avg Vol	3,292,412
Day's Range	N/A - N/A
Shares Out	303.16M
Stochastic %K	95%
Beta	0.85
Analysts	Strong Sell
Price Target	$9.43